Transcribed

The 2012 Great Patent Cliff

SINGULAIR (ASTHMA) $1.3 BILLION THE 2012 PATENT CLIFF LEXAPRO (DEPRESSION & ANXIETY) $2.3 BILLION MPK 117 ENBREL (ARTHRITIS) $3.3 BILLION 8 DRUG PATENTS EXPIRE IN 2012, OPENING THEM TO GO GENERIC. ACTOS (DIABETES) $3.3 BILLION SEROQUEL (SCHIZOPHRENIA & BIPOLAR DISORDER) $3.7 BILLION IN 2011, THESE 8 DRUGS ACCOUNTED FOR 2010 TOTAL DIOVAN (HYPERTENSION & HEART FAILURE) $4.3 BILLION DRUG SALES WERE $307 $33 BİLLION PLAVIX (HEART ATTACK & STROKE) $7.1 BILLION BILLION IN REVENUE. THE LOSS IN 2010, GENERIC DRUGS OF THESE PATENTS ADVAIR (ASTHMA & COPD) $8.1 BILLION WILL COST AS MANY AS ACCOUNTED FOR 12,000 78% BIG PHARMA JOBS. OF ALL DRUG SALES ON AVERAGE, THE COST IN 2010, FDA-APPROVED OF A GENERIC DRUG IS GENERIC DRUGS SAVED $158 5-6 TIMES Brought to you by MI2FIT www.misfitwearables.com/references BILLION LOWER THAN THE BRAND NAME PRODUCT. ADVAIR II

The 2012 Great Patent Cliff

shared by misfit_wearables on Sep 13

1,086 views

1 fave

1 shares

0 comments

The great 2012 patent cliff is about the eight drug major drug patents expiring in 2012. This means they can made as generics (not branded) by other companies, meaning much cheaper drugs for everyone,... and much less money for a few big companies. This in turn will result in some people losing their jobs, even while new jobs are created at the generic manufacturers. Are these jobs more important then cheaper drugs for everyone else? Who is affected most by the drugs involved? We post a new infographic every fortnight so be sure to visit http://www.misfitwearables.com/ occasionally to see the new infographic we have posted. References: The drugs going off patent in 2012- http://bit.ly/Prb054 Generic drugs accounted for 78% of all drug sales - http://n.pr/SIteNx The cost of a generic drug is 80 to 85 percent lower - http://1.usa.gov/RbHZuL 2010 total drug sales were $307B - http://bit.ly/SeCJIe In 2010 FDA-approved generics drugs saved $158 billion - http://1.usa.gov/RbHZuL

Publisher

Misfit Wearables